SLC5A2 and kidney disorder: Specifically, SGLT2 inhibitors significantly reduced the composite renal endpoints (progression to macro-albuminuria, serum creatinine doubling, the start of renal replacement therapy (RRT), or death resulting from the renal disease [13,14,5]. While SGLT2 inhibitors, through different mechanisms, lower blood glucose, body weight, improve hematocrit and blood pressure, as a result, predicting the net effect of SGLT2 inhibitors on CV outcomes was difficult.